<DOC>
	<DOCNO>NCT01585766</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ascend intravenous ( IV ) subcutaneous ( SC ) dose MEDI-551 adult subject relapse form multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Safety Tolerability Study MEDI-551 , B-cell Depleting Agent , Treat Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description>This Phase 1 , multicenter , multinational , randomize , blind , placebo-controlled , dose-escalation study evaluate safety tolerability IV SC dose MEDI-551 adult subject relapse form MS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Confirmed relapse form MS ( ie , RRMS , SPMS , PRMS , CIS ) accord revise 2010 McDonald criterion MRI brain lesion consistent MS screening At least 1 documented relapse within past 3 year prior screen EDSS 0.0 6.5 screening Have 20 Gdenhancing T1 brain lesion detect cranial MRI scan Subjects impair renal function Major surgery within 8 week screen visit Subjects unable undergo cranial MRI scan A history hypersensitivity Gdcontaining MRI contrast agent Has receive within 1 year prior screening : monoclonal antibody , experimental Bcell deplete agent , treatment natalizumab ( Tysabri ) great 3 month Receiving monthly methylprednisone equivalent glucocorticoid disease modification relapse form MS Known sensitivity acetaminophen/paracetamol , diphenhydramine equivalent antihistamine , methylprednisolone equivalent glucocorticoid , component investigational drug Diagnosis PPMS , neuromyelitis optica , nonMS variant neuroinflammatory demyelinate disease Any history opportunistic infection presence active infection within two month prior screen herpes zoster infection resolve within 12 week prior screen Any clinically significant finding screen phase , include physical , neurological , laboratory , ECG examination per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MAb , B cell , depletion , RMS</keyword>
</DOC>